| Literature DB >> 29849735 |
Ana Liu1, Yan-Jun Chu2, Xiaoming Wang1, Ruixue Yu1, Haiqiang Jiang3, Yunlun Li2, Honglei Zhou1, Li-Li Gong3, Wen-Qing Yang2, Jianqing Ju2.
Abstract
Our previous studies have shown that Uncaria has an important role in lowering blood pressure, but its intervention mechanism has not been clarified completely in the metabolic level. Therefore, in this study, a combination method of HPLC-TOF/MS-based metabolomics and multivariate statistical analyses was employed to explore the mechanism and evaluate the antihypertensive effect of Uncaria. Serum samples were analyzed and identified by HPLC-TOF/MS, while the acquired data was further processed by partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) to discover the perturbed metabolites. A clear cluster among the different groups was obtained, and 7 significantly changed potential biomarkers were screened out. These biomarkers were mainly associated with lipid metabolism (dihydroceramide, ceramide, PC, LysoPC, and TXA2) and vitamin and amino acids metabolism (nicotinamide riboside, 5-HTP). The result indicated that Uncaria could decrease the blood pressure effectively, partially by regulating the above biomarkers and metabolic pathways. Analyzing and verifying the specific biomarkers, further understanding of the therapeutic mechanism and antihypertensive effect of Uncaria was acquired. Metabolomics provided a new insight into estimate of the therapeutic effect and dissection of the potential mechanisms of traditional Chinese medicine (TCM) in treating hypertension.Entities:
Year: 2018 PMID: 29849735 PMCID: PMC5904782 DOI: 10.1155/2018/9281946
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Systolic blood pressure changes in 4-week consecutive administration (mmHg). Note. p < 0.05 compared with model group.
Figure 2HPLC-MS extract ion chromatogram (EIC) of serum samples from the normal group (a), the model group (b), and the Uncaria-treated group (c).
Figure 3The comparison of results before and after ion regression analysis.
Figure 4PLS-DA score plot (a) (1: model group; 2: normal group; 3: Uncaria group) and validated model plots (b) based on the HPLC-MS data.
Figure 5Multivariate analysis of untargeted metabolomics data. (a) OPLS-DA score plots of serum metabolic profiling of model group (1) and Uncaria group (2). (b) Loading plots constructed from the supervised OPLS-DA. (c) S-plot constructed from the supervised OPLS-DA. (d) VIP-score plots constructed from the supervised OPLS-DA. The loading plot, S-plot, and VIP plot were carried out to select distinct variables as potential biomarkers.
Potential biomarkers in samples and corresponding metabolic pathways.
| Number | RT | Mass | Biomarker | KEGG | Change trend | Pathway | |
|---|---|---|---|---|---|---|---|
| Trenda | Trendb | ||||||
| (1) | 15.64 | 329.3297 | Dihydroceramide | C12126 | ↑ | ↓ | Sphingolipid metabolism |
| (2) | 28.35 | 563.441 | Ceramide | C00195 | ↑ | ↓ | Sphingolipid metabolism |
| (3) | 29.94 | 701.2065 | PC(16:1(9Z)/14:1(9Z)) | C00416 | ↓ | ↑ | Glycerophospholipid |
| (4) | 18.39 | 569.3487 | LysoPC (22:5) | C04230 | ↑ | ↓ | Glycerophospholipid |
| (5) | 26.68 | 296.2828 | Thromboxane A2 | C02198 | ↑ | ↓ | Arachidonic acid metabolism |
| (6) | 26.68 | 255.2564 | Nicotinamide riboside | C03150 | ↓ | ↑ | Nicotinate and nicotinamide |
| (7) | 0.68 | 220.1793 | 5-HTP | C00643 | ↑ | ↓ | Tryptophan metabolism |
Note. aTrends of model group compared with normal group of metabolites. p < 0.05 compared to normal group. bTrends of Uncaria group compared with model group of metabolites. p < 0.05 compared to model group. ↑: upregulated. ↓: downregulated.
Figure 6Comparison of different potential biomarkers of normal group, model group, and Uncaria-treated group. p < 0.05 compared to model group.
Figure 7The network of the potential biomarkers variation for SHRs with or without Uncaria modulation.